- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03485417
Substance Misuse To Psychosis for Stimulants
July 2, 2023 updated by: Dr. Albert Kar-Kin Chung, The University of Hong Kong
Substance Misuse To Psychosis for Stimulants (SToP-S)--An Early Assertive Pharmacotherapy Intervention Study
In Hong Kong, less than 5% of stimulants abusers were reported to misuse these substances via injection.
Also, it is well known that patients with co-morbid substance abuse/dependence and psychosis or schizophrenia-related disorders are prone to earlier treatment discontinuation and high oral medication non-adherence, resulting in poorer overall outcomes.
With the recent availabilities of the 4-weekly long-acting injectable form of aripiprazole, and the 4-weekly and the 3-monthly long-acting injectable form of paliperidone palmitate, on the background of the surging phenomenon of stimulant misuses in Hong Kong, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with substance use disorders with psychosis to develop into a more chronic disabling dependence or co-morbid state.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: albert KK Chung, Dr
- Phone Number: +85222553060
- Email: chungkka@hku.hk
Study Locations
-
-
-
Hong Kong, Hong Kong, 000000
- Recruiting
- Queen Mary Hospital
-
Contact:
- Albert KK Chung
- Phone Number: 2255 3067
- Email: chungkka@hku.hk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 50 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
• Stimulant use disorder with psychosis or positive stimulant urine test results twice in a month with psychosis
Exclusion Criteria:
- Age <16 years old
- Unable to read English or Chinese
- Unable to give informed consent
- Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
- Had been diagnosed to have Schizophrenia
- Had been diagnosed to have other substance-induced psychotic or mood disorder, including alcohol
- Had been diagnosed to have bipolar disorder viii. Had been diagnosed to have major depressive disorder with psychotic features
- Had been taking any maintenance dose of oral antipsychotics continuously ≥12 weeks AND with psychotic symptoms in remission
- Had been receiving any maintenance dose of long-acting injectable (LAI/depot) antipsychotics continuously ≥4 month AND with psychotic symptoms in remission
- Had known hypersensitivity to risperidone (oral or LAI), paliperidone (oral or LAI), or aripiprazole (oral or LAI)
- Had known history of tardive dyskinesia
- Had known history of neuroleptic malignant syndrome
- Pregnant
- Mother currently breast-feeding
- Had history of prolonged corrected QT interval (QTc) ≥500ms and/or known unstable or untreated cardiac disorder
- Had mild to severe renal impairment with Glomerular Filtration Rate <80 mililitre /min
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aripiprazole Arm
Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
|
for oral or depot preparation
|
Active Comparator: Paliperidone Arm
Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
|
for oral or depot
|
Other: Treatment as Usual Arm
Treatment as Usual arm
|
to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative risk of psychosis relapse
Time Frame: 36 months
|
The risk of relapse (rate and relative risk) for subjects receiving the active treatments with paliperidone and aripiprazole as compared to treatment as usual
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
transition from diagnosis of substance induced psychosis to Schizophrenia as defined by DSM-5
Time Frame: 36 months
|
The rate of transition from substance induced psychosis To schizophrenia in all 3 different arms
|
36 months
|
change in stimulant use disorder as defined by DSM-5
Time Frame: At 12th month and at 36th month
|
The change is severity of the Stimulant Use Disorder in subjects in the 3 different arms by DSM-5 criteria
|
At 12th month and at 36th month
|
Montreal Cognitive Assessment (MoCA)
Time Frame: At 12th month and at 36th month
|
Difference in cognitive outcome measured using MoCA in subjects randomized to the 3 arms
|
At 12th month and at 36th month
|
Addiction Severity Index (ASL)-lite
Time Frame: At 12th and 36th months
|
Difference in functional outcome measured using ASL-lite in subjects randomized to the 3 treatment arms
|
At 12th and 36th months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: albert KK Chung, Dr, The University of Hong Kong
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2019
Primary Completion (Estimated)
May 31, 2024
Study Completion (Estimated)
May 31, 2025
Study Registration Dates
First Submitted
March 14, 2018
First Submitted That Met QC Criteria
March 25, 2018
First Posted (Actual)
April 2, 2018
Study Record Updates
Last Update Posted (Actual)
July 5, 2023
Last Update Submitted That Met QC Criteria
July 2, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Psychotic Disorders
- Mental Disorders
- Shared Paranoid Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Aripiprazole
- Paliperidone Palmitate
Other Study ID Numbers
- SToP-S
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia and Related Disorders
-
Northwell HealthWinterlight LabsCompletedSchizophrenia and Related DisordersUnited States
-
University of Maryland, BaltimoreRecruiting
-
Vanderbilt University Medical CenterCompletedSchizophrenia and Related DisordersUnited States
-
Örebro University, SwedenActive, not recruitingSchizophrenia and Related DisordersSweden
-
Fundación Pública Andaluza para la gestión de la...Completed
-
University of BernCompletedSchizophrenia and Related DisordersSwitzerland
-
Weill Medical College of Cornell UniversityUniversity of Catania; University of Stirling; Hunter College of The City University...CompletedSchizophrenia and Related DisordersUnited States
-
Haukeland University HospitalRecruitingBipolar Disorder | Schizophrenia and Related DisordersNorway
-
National Taiwan University HospitalRecruitingSchizophrenia and Related DisordersTaiwan
-
University of BernTerminatedSchizophrenia and Related DisordersSwitzerland
Clinical Trials on Aripiprazole
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityCompleted
-
Otsuka Beijing Research InstituteCompleted
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaUnited States
-
University of California, Los AngelesAlkermes, Inc.TerminatedSchizophrenia | Schizophreniform Disorder | Schizoaffective Disorder, Depressive TypeUnited States
-
Otsuka Pharmaceutical Co., Ltd.CompletedMajor Depressive DisorderJapan
-
Veterans Medical Research FoundationBristol-Myers SquibbCompleted
-
Otsuka Pharmaceutical Co., Ltd.CompletedSchizophreniaJapan
-
Otsuka Pharmaceutical Development & Commercialization...CompletedSchizophreniaKorea, Republic of, United States, Estonia, Italy, Hungary, Bulgaria, Croatia, France, Poland, Thailand, Puerto Rico, Chile, South Africa, Austria, Belgium
-
Alkermes, Inc.CompletedSchizophreniaUnited States
-
Alkermes, Inc.CompletedSchizophreniaUnited States